The promising outcomes from the phase I CHRYSALIS study have led to the phase III PAPILLON study, a randomized open-label trial evaluating the efficacy of amivantamab combined with chemotherapy versus chemotherapy alone as a first-line treatment for EGFR exon 20 insertion mutations in NSCLC patients [35]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.